IRLAB Therapeutics — EMA alignment on mesdopetam Phase III plans
IRLAB has bolstered the value of its lead programme, mesdopetam in levodopa-induced dyskinesias (PD-LIDs), following confirmation that the European...
221 Views
IRLAB Therapeutics — Pirepemat stumbles in Phase IIb study
IRLAB has announced top-line results for its Phase IIb trial assessing pirepemat’s potential to improve balance and reduce falls in Parkinson’s...
210 Views
IRLAB Therapeutics — Next steps laid out for IRL757
IRLAB has confirmed that clinical candidate IRL757, which has been designed to address apathy in patients with neurodegenerative conditions, will...
226 Views
No more insights